Duopharma Biotech Posts Strong Growth in 3Q 2021
• 3Q PBT rises 21% to RM22.48 million as compared to previous corresponding quarter
• Greater Government emphasis on pharmaceutical sector in mid-term plan and increased budget allocation
for healthcare in Budget 2022 bode well for future earnings